Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-naïve and previously treated patients with pemphigus vulgaris after receiving rituximab

• প্রধান লেখক: Hoorieh Alaeen, MD (লেখক), Roja Toosi, MD, MPH (লেখক), Hamidreza Mahmoudi, MD (লেখক), Kamran Balighi, MD (লেখক), Soheil Tavakolpour, MS (লেখক), Amir Teimoupour, PhD (লেখক), Maryam Daneshpazhooh, MD (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Wolters Kluwer, 2019-12-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

Background: Pemphigus vulgaris (PV) is a blistering, life-threatening autoimmune disease. Ethylenediaminetetraacetic acid (EDTA)-treated desmoglein (Dsg) enzyme-linked immunosorbent assay (ELISA) has recently been suggested to detect nonpathogenic antibodies. Rituximab (RTX) is now considered a firs...